TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02891382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes education
Description: Participants interact with a diabetes educator (DE), every two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes education
Description: Participants interact with a diabetes educator (DE), every two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes education
Description: Participants interact with a diabetes educator (DE), every two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting
Description: Goals for weight loss and change in levels of HbA1c

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting
Description: Goals for weight loss and change in levels of HbA1c

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting
Description: Goals for weight loss and change in levels of HbA1c

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Companion Support
Description: Patient has a companion/team support partner to support achieving goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Companion Support
Description: Patient has a companion/team support partner to support achieving goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Reward
Description: The cash reward is given to the patient with diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Reward
Description: The cash reward is given to the patient with diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Reward
Description: Patients with diabetes and their companion support will each receive 50% of the cash reward.
Study: NCT03679026

Intervention type: OTHER
Intervention: Summarize of participants' characteristics using means and standard deviations or frequencies and percentages
Description: Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.

Intervention type: OTHER
Intervention: Summarize of participants' characteristics using means and standard deviations or frequencies and percentages
Description: Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
Study: NCT00961714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoFix Spinal Fracture Reduction System
Description: All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
Study: NCT03365700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
Study: NCT05735301

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA
Study: NCT00693524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IL2R AB
Description: i.v.
Study: NCT05735301

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA

Intervention type: DRUG
Group type: OTHER
Intervention: Drug
Description: best drug conservative therapy could be uesd in patients who with no indication of surgery
Study: NCT00723359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT062
Description: biologic
Study: NCT06430723

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty using short stem via an minimally invasive anterolateral approach

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty using short stem via an minimally invasive anterolateral approach
Study: NCT00644111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine, Hydromorphone
Description: 0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
Study: NCT03244826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Care
Description: Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: The usual care provided by the transplant center at DFCI.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: The usual care provided by the transplant center at DFCI.
Study: NCT03080636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 30 minutes of treadmill exercise at 60-70% of heart rate reserve
Study: NCT00693524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral
Study: NCT03080636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 30 minutes of treadmill exercise at 60-70% of heart rate reserve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 30 minutes of circuit resistance session at 40% of 1 maximun repetition test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 30 minutes of circuit resistance session at 40% of 1 maximun repetition test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control session
Description: 30 minutes seated resting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control session
Description: 30 minutes seated resting
Study: NCT04356040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiFlex SE
Description: Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
Study: NCT04177940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMAB Discontinuation and Switching
Description: Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose
Study: NCT04356040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiFlex SE - High Standard Power
Description: Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
Study: NCT01836926

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open intersphincteric resection
Description: laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transanal minimally invasive intersphincteric resection
Description: minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
Study: NCT02014779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eChange
Description: A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face therapy
Description: Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
Study: NCT00697710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg S-777469
Description: S-777469, 50 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg S-777469
Description: S-777469, 200 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg S-777469
Description: S-777469, 800 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT01008904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium oxide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02243891

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: Percutaneous catheter ablation for Atrial fibrillation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: Percutaneous catheter ablation for Atrial fibrillation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROX Coupler insertion
Description: The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
Study: NCT04330027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth factors
Description: A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% Sodium Chloride
Study: NCT04394650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CC-98633
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection.
Study: NCT00336557

Intervention type: PROCEDURE
Intervention: NAbs testing
Description: blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
Study: NCT05735301

Intervention type: DRUG
Group type: OTHER
Intervention: Drug
Description: best drug conservative therapy could be uesd in patients who with no indication of surgery
Study: NCT02355444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: blackberry polyphenol enriched beverage
Description: Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: blackberry beverage with minimal polyphenol concentrations
Description: Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
Study: NCT01138501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
Study: NCT03815565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous femoral block
Description: infusion of anesthetic by PCA pump

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous femoral block
Description: infusion of anesthetic by PCA pump
Study: NCT02073019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02294344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFPP&CTX
Description: First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35\~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study.
Study: NCT00263068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day
Study: NCT03571581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Description: Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
Study: NCT00729183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 50 mg tablets, taken orally once weekly for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to odanacatib taken orally once weekly for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium supplement
Description: Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
Study: NCT02331147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dressing Application
Description: Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
Study: NCT02073019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03657095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esuberaprost
Description: Sodium tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esuberaprost
Description: Sodium tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
Study: NCT01381549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem-cilastatin
Description: Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: saline placebo
Study: NCT02917148

Intervention type: OTHER
Intervention: Peripheral Venipuncture or Blood draw from Central Line
Study: NCT01455779

Intervention type: DEVICE
Group type: OTHER
Intervention: Lyrette
Description: The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment.
Study: NCT02441829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally in morning with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally in morning with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally in morning with food
Study: NCT00824057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: oral
Study: NCT04776122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Device-assisted breathing for relaxation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No device
Description: Breathing platform without device
Study: NCT02723799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hope Promotion Program (HPP)
Description: HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment Protocol
Description: Regular assessment and care by the hospital outpatient health care team.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment Protocol
Description: Regular assessment and care by the hospital outpatient health care team.
Study: NCT03425175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-recoring
Description: Recording of audio through microphone carried bu surgeon and assistant surgeon
Study: NCT00690313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox
Description: eye drops 3 times day either 1 or 3 days prior to intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox
Description: eye drops 3 times day either 1 or 3 days prior to intravitreal injection